泌尿道感染治疗市场，按药物、适应症和地理划分 - 规模、份额、前景和机会分析，2024 年至 2031 年

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

出版日期: 2024年03月11日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计 2024 年全球泌尿道感染治疗市场价值为 93.9 亿美元，预计在预测期内（2024-2031 年）复合年增长率为 3%。

报告范围		报告详情
基准年：	2023年	2023/2024 年市场规模：	93.9 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测期间 2023/2024 至 2030/2031 年复合成长率：	3.00%	2030/2031 价值预测：	115.8 亿美元

2024 年全球泌尿道感染治疗市场价值（十亿美元），按地区划分

泌尿道感染 (UTI) 是泌尿系统任何部位的感染。与男性相比，女性罹患泌尿道感染的风险更大。泌尿道感染 (UTI) 通常是由粪便细菌进入泌尿道引起的。抗生素通常是泌尿道感染的首选治疗方法。治疗单纯性泌尿道感染的常用药物包括甲氧芐啶和磺胺甲噁唑（Bactrim、Bactrim DS）、磷霉素（Monurol）、呋喃妥因（Macrodantin、Macrobid 和 Furadantin）、头孢氨芐和头孢曲松。

市场动态：

泌尿道感染的高盛行率、糖尿病和肾结石盛行率的增加、老年人口的增加以及对新型疗法开发的关注增加是预计在预测期内推动全球尿路感染治疗市场成长的一些主要因素。

2021年10月，Spero Therapeutics Inc.向美国食品药物管理局（USFDA）提交了新药申请（NDA），寻求批准氢溴酸替比培南片剂用于治疗复杂性泌尿道感染（cUTI），包括肾盂肾炎，此感染由以下原因引起：易感微生物。此外，2021年9月，BDR Pharma推出了比阿培南，用于治疗腹内感染、下呼吸道感染或复杂性泌尿道感染患者。

2019 年7 月，美国食品药物管理局(FDA) 批准了Recarbrio（亚胺培南、西司他丁和瑞巴坦），这是一种抗菌药物产品，用于治疗成人复杂性泌尿道感染(cUTI) 和复杂性腹腔内感染(cIAI)。

研究的主要特点：

该报告对全球尿路感染治疗市场进行了深入分析，并提供了预测期（2024-2031）的市场规模和年复合成长率（CAGR%），以2023年为基准年。
它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数（例如公司亮点、产品组合、主要亮点、财务表现和策略）介绍了全球尿路感染治疗市场的主要参与者。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球尿路感染治疗市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球尿路感染治疗市场的各种策略矩阵轻鬆做出决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 9.39 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	3.00%	2030/2031 Value Projection:	US$ 11.58 Bn

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2019, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

Global Urinary Tract Infection Therapeutic Market By Drug:
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
Global Urinary Tract Infection Therapeutic Market By Indication;
- Complicated UTI
- Uncomplicated UTI
- Other Indications
Global Urinary Tract Infection Therapeutic Market By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Company Profiles:
- Pfizer
- Novartis AG
- Cipla Inc.
- Bayer AG
- AstraZeneca
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC

Market Dynamics
- High prevalence of urinary tract infection across the globe
- Adverse effects associated with the use of UTI medication
- Increase in focus on the development of novel drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Penicillin and Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Azoles and Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Nitrofurans
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)

8. Competitive Landscape

Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies